Merck Invests $30mln in Eikon Therapeutics, Enters Multi-Year Oncology Pact with Guardant Health

Merck has invested $30 million in Eikon Therapeutics and entered a multi-year oncology collaboration with Guardant Health. These deals aim to extend Merck's reach in oncology and cancer diagnostics beyond its regular earnings activity. The partnerships give Merck access to Eikon's pipeline and Guardant's testing capabilities, potentially leading to approved products, additional revenue sources, and continued relevance in cancer care over the coming years.